New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled “A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis” will appear in the August 21, 2025, online version of the publication and can be found at www.nejm.org. Following the onlin
Related Questions
How will the publication of the Phase 3 IMPALA-2 results in NEJM affect Savara's stock valuation and short‑term price movement?
What are the key efficacy and safety data points from the IMPALA-2 trial, and how do they compare to existing therapies for autoimmune PAP?
When can investors expect regulatory filing or FDA approval timelines based on these Phase 3 results, and what market size estimates support revenue forecasts?